KN026

Phase 3Small molecule

JJiangsu Alphamab Biopharmaceuticals Co., Ltd

KN026 is one of 143 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

142

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerNot yet recruiting

Colorectal CancerNot yet recruiting

Gastric CancerNot yet recruiting

HER2-Positive Breast CancerActive, not recruiting

Locally AdvancedRecruiting

Breast CancerPhase 3

Not yet recruiting

Colorectal CancerPhase 2

Not yet recruiting

Gastric CancerPhase 3

Not yet recruiting

HER2-Positive Breast CancerPhase 3

Active, not recruiting

Locally AdvancedPhase 2

Recruiting

Competition

Competitive Landscape

702 competitors in Breast Cancer

#DrugCompanyPhaseTrials

KN026

JJiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 3

4 2

Ablavar

LLantheus Medical Imaging

Preclinical

2 3

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 4

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 5

Lapatinib Plus Capecitabine

GSK

Preclinical

2 6

Therapeutic Progesterone

EEmory University

Preclinical

1 7

Determination of ESR1 Mutations

CCentre Henri Becquerel

Preclinical

1 8

Midazolam Premedication

YYonsei University

Preclinical

1 9

Combination NRT

UUniversity of Alabama at Birmingham

Preclinical

1 10

Calendula

OOHSU Knight Cancer Institute

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Locally Advanced

NCT06023758

Phase 2Not yet recruiting

Colorectal Cancer

NCT05985707

Q4 2027

Phase 3Active, not recruiting

HER2-Positive Breast Cancer

NCT06747338

Q4 2029

Phase 2Not yet recruiting

Gastric Cancer

NCT06998771

Q4 2032

Phase 2/3Not yet recruiting

Gastric Cancer

NCT07332533

Clinical

Trials by Indication[1]

Breast Cancer4 trials

Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer

Unknown status·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 2·NCT04165993·68 enrolled

Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer

Terminated·JJiangsu Alphamab Biopharmaceuticals Co., Ltd··NCT04778982·4 enrolled

Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Unknown status·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 2·NCT04881929·30 enrolled

Show 1 more trial

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT07441460·1,800 enrolled

Gastric Cancer4 trials

Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer

Completed·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 1·NCT03619681·63 enrolled

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 2/3·NCT07332533·490 enrolled

KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer

Unknown status·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 1·NCT03847168·22 enrolled

Show 1 more trial

JSKN003 Combined Treatment of HER2-positive Gastric Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 2·NCT06998771·153 enrolled

Locally Advanced1 trial

Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC

Recruiting·PPeking University·Phase 2·NCT06023758·18 enrolled

HER2-Positive Solid Tumor1 trial

Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors

Completed·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 2·NCT04521179·102 enrolled

Gastric/Gastroesophageal Junction Cancer1 trial

KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer

Completed·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 2·NCT03925974·45 enrolled

2 more indications

Colorectal Cancer1 trial

KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma

Not yet recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT05985707·80 enrolled

HER2-positive Breast Cancer1 trial

A Randomized, Controlled, Open-label, Multicenter, Phase III Clinical Trial to Compare the Efficacy and Safety of KN026 Combined With HB1801 ± Carboplatin Versus Trastuzumab Combined With Pertuzumab and Docetaxel ± Carboplatin in Neoadjuvant Treatment of Early or Locally Advanced HER2-positive Breast Cancer.

Active, not recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT06747338·520 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for KN026. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KN026 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KN026. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu Alphamab Biopharmaceuticals Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJiangsu Alphamab Biopharmaceuticals Co., Ltd

KN026

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q4 2029

Q4 2032

Trials by Indication[1]

Breast Cancer4 trials

Gastric Cancer4 trials

Locally Advanced1 trial

HER2-Positive Solid Tumor1 trial

Gastric/Gastroesophageal Junction Cancer1 trial

Colorectal Cancer1 trial

HER2-positive Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News